^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | ProstAtak (aglatimagene besadenovec) (Gene transference, Thymidine kinase stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
Published date:
09/26/2023
Excerpt:
Candel Therapeutics...announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy....Amongst patients alive ≥ 12 months with known PD-L1 status (14/15), 93% had negative or low PD-L1 score (<1 or between 1-49).
Secondary therapy:
Immunotherapy + valacyclovir
